Can low free T3 raise LDL cholesterol even when TSH and free T4 are normal?

Thyroid hormones play a critical role in systemic lipid metabolism, directly influencing how the liver clears cholesterol from the bloodstream.

Mechanistic pathways of hepatic receptor regulation

• Direct transcriptional control: Active triiodothyronine (T3) is a primary transcriptional regulator of hepatic low-density lipoprotein receptors (LDLR). It directly binds to thyroid hormone receptors to upregulate LDLR gene expression at the promoter level.
• SREBP-2 pathway activation: T3 indirectly enhances LDLR expression by modulating sterol regulatory element-binding protein-2 (SREBP-2), a key master transcription factor. A reduction in free T3 diminishes SREBP-2 activation, leading to a concurrent downregulation of hepatic LDLR mRNA and protein expression.

Impact on LDL clearance and systemic lipid levels

• Impaired receptor endocytosis: Because receptor-mediated endocytosis is the primary pathway for clearing LDL particles from circulation, a decrease in hepatic LDLR activity extends the half-life of these atherogenic particles in the blood.
• Tissue-level hypothyroidism: This metabolic impairment can occur even when traditional thyroid markers—thyroid-stimulating hormone (TSH) and free thyroxine (T4)—remain within normal reference ranges. This presentation often reflects impaired peripheral conversion of T4 to T3 or localized tissue-level hypothyroidism, which is sufficient to reduce hepatic LDLR activity and elevate circulating LDL cholesterol.

Bottom line

• Isolated low free T3, despite normal TSH and free T4, reduces hepatic LDLR expression through both direct transcriptional inhibition and reduced SREBP-2 activity, ultimately impairing systemic LDL clearance and contributing to elevated circulating LDL cholesterol.